Create a narrative

Taysha Gene Therapies Community

NasdaqGS:TSHA Community

1 Narratives written by author
0 Comments on narratives written by author
13 Fair Values set on narratives written by author

Create a narrative

Taysha Gene Therapies

AN

AnalystConsensusTarget

AnalystConsensusTarget

Consensus Narrative from 11 Analysts

FDA Meetings And TSHA-102 Trials Will Advance Approval

Key Takeaways Advancements in TSHA-102 trials and regulatory discussions could expedite approval and boost future revenue and investor confidence. Strategic alignment with regulatory and market priorities could enhance trial success, market adoption, and long-term revenue growth.

US$8.32

FV

67.1% undervalued

123.23%

Revenue growth p.a.

0

0

10

Updated